---
title: "Fulcrum Therapeutics, Inc. (FULC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/FULC.US.md"
symbol: "FULC.US"
name: "Fulcrum Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-03-13T08:38:53.517Z"
locales:
  - [en](https://longbridge.com/en/quote/FULC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/FULC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/FULC.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/FULC.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/FULC.US.md)


# Fulcrum Therapeutics, Inc. (FULC.US)

## Company Overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.fulcrumtx.com](https://www.fulcrumtx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-13T04:30:15.000Z

**Overall: D (0.73)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 188 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -669.97% |  |
| P/B Ratio | 1.46 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 508159594.67 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -31.21% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -297.00% | E |
| Total Assets YoY | -22.99% | E |
| Net Assets YoY | -22.90% | E |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | -100.00% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 7.68% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Fulcrum Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-669.97%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.46",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "508159594.67",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-31.21%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-297.00%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-22.99%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-22.90%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "7.68%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.79 | 170/188 | - | - | - |
| PB | 1.46 | 72/188 | 3.28 | 1.83 | 1.50 |
| PS (TTM) | 5.27 | - | 5.27 | 5.27 | 4.35 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | C | B |
| 03 | Roche (RHHBY.US) | A | B | B | D | C | B |
| 04 | AstraZeneca (AZN.US) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (NVS.US) | A | B | C | D | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-11T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 60% |
| Overweight | 1 | 10% |
| Hold | 1 | 10% |
| Underweight | 1 | 10% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.63 |
| Highest Target | 25.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/FULC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/FULC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/FULC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/FULC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**